Poly (glycerol adipate) (PGA): From a functionalized nano-carrier to a polymeric-prodrug matrix to create amorphous solid dispersions.
Amorphous Solid Dispersions (ASDs) are a promising strategy to overcome poor-solubility and stability limitations, reducing the crystallinity of the drug through incorporation within a polymer matrix. However, in order to achieve an effective ASD, the polymer and drug must be compatible, otherwise the drug can undergo recrystallisation. In this work, we investigated the potential of the enzymatically synthesized poly(glycerol-adipate)(PGA), as a pharmaceutical tool for producing a nano-amorphous formulation. A polymeric prodrug of PGA was synthesized by coupling mefenamic acid as drug. The amorphicity of the polymeric prodrug was assessed combining differential scanning calorimetry and polirized optical microscopy. The prodrug was then formulated into nanoparticles(NPs) and studied for stability and drug release in the presence of lipase. To realize the goal of combination drug therapies for overcoming drug resistance and improving treatment outcomes, the prodrug was screened as a solubility enhancer for a series of fenamic-drugs and compared to commercially available polymers commonly used in solid dispersions. Screening was carried out by developing a high-throughput miniaturized screening assay using a 2D-printer to dispense the polymer and drug combinations. Finally, the collected data showed that drug-conjugation could improve drug-polymer compatibility, in addition to facilitating the release of drugs by two different mechanisms.